Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.59 |
| ▸ | DNMT3L | Q9UJW3 | 4/20 | 0.59 |
| ▸ | DNMT3A | Q9Y6K1 | 4/20 | 0.59 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13963126 | 0.92 | CYP1A2 (0.57) | CYP1A2CYP2D6DNMT1DNMT3LDNMT3A | |
| SCHEMBL13963099 | 0.89 | ROCK1 (0.66) | CYP1A2CYP2D6DNMT1DNMT3LDNMT3A | |
| SCHEMBL12240383 | 0.89 | TP53 (0.69) | CYP1A2CYP2D6DNMT1DNMT3LDNMT3A | |
| Hydrochloric Acid SCHEMBL4523591 | 0.88 | ROCK1 (0.64) | CYP1A2CYP2D6DNMT1DNMT3LDNMT3A | |
| Hydrochloric Acid SCHEMBL2537439 | 0.88 | TP53 (0.67) | CYP1A2CYP2D6DNMT1DNMT3LDNMT3A | |
| SCHEMBL3500528 | 0.86 | DNMT1 (0.60) | CYP1A2CYP2D6DNMT1DNMT3LDNMT3A | |
| Trifluoroacetic Acid SCHEMBL4529644 | 0.85 | CYP1A2 (0.52) | CYP1A2CYP2D6DNMT1DNMT3LDNMT3A | |
| SCHEMBL3501270 | 0.85 | DNMT1 (0.75) | CYP1A2CYP2D6DNMT1DNMT3LDNMT3A | |
| SCHEMBL13963133 | 0.83 | CYP1A2 (0.58) | CYP1A2CYP2D6DNMT1DNMT3LDNMT3A | |
| SCHEMBL12240489 | 0.83 | DNMT1 (0.72) | CYP1A2CYP2D6DNMT1DNMT3LDNMT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137566-A1 | Compounds and Methods Used to Treat Infectious Diseases | CYTOKINE PHARMASCIENCES, INC (US) | 2010-06-03 | — | — | US | disclosed |
| US-20060014760-A1 | Compounds and methods of use to treat infectious diseases | BUKRINSKY MICHAEL I | 2006-01-19 | — | — | US | disclosed |
| US-6906076-B2 | Compounds and methods of use to treat infectious diseases | CYTOKINE PHARMASCIENCES, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040053815-A1 | Compounds and methods of use to treat infectious diseases | FERRING BV (NL) | 2004-03-18 | — | — | US | disclosed |
| EP-0865434-B1 | COMPOUNDS AND THEIR USE TO TREAT INFECTIOUS DISEASES | PICOWER INST MED RES (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6649797-B2 | Contacting protein with a compound that is capable of stable reversible binding with basic amino acid residues of nuclear localization signal of protein for inactivating a nuclear localization signal of a protein | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2003-11-18 | — | — | US | disclosed |
| US-20020077271-A1 | Compounds and methods of use to treat infectious diseases | FERRING BV (NL) | 2002-06-20 | — | — | US | disclosed |
| US-6297253-B1 | INACTIVATING A NUCLEAR LOCALIZATION SIGNAL OF A PROTEIN COMPRISING CONTACTING THE PROTEIN WITH AN ARYL CARBONYL COMPOUND THAT FORMS STABLE REVERSIBLE COVALENT INTERACTIONS WITH NEIGHBORING BASIC AMINO ACID RESIDUES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2001-10-02 | — | — | US | disclosed |
| US-5840893-A | TREATING MALARIA, HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0865434-A1 | COMPOUNDS AND METHODS OF USE TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-09-23 | — | — | EP | disclosed |
| EP-0865434-A4 | — | — | 1998-09-23 | — | — | EP | disclosed |
| WO-1998016515-A1 | COMPOUNDS AND METHODS TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5733932-A | VIRICIDES MARKING AND BLOCKING SPECIFIC VIRAL PROTEINS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-03-31 | — | — | US | disclosed |
| US-5703086-A | TREATMENT OF HIV INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-12-30 | — | — | US | disclosed |
| US-5620983-A | BLOCKING MOVEMENT OF VIRAL GENOME PARTICLES THROUGH NUCLEAR MEMBRANE IN TERMINALLY DIFFERENTIATED CELLS TO PREVENT VIRAL INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-04-15 | — | — | US | disclosed |
| US-5574040-A | DIALKANOYLPHENYLPYRIMIDINE DERIVATIVES | PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1996020932-A1 | COMPOUNDS AND METHODS OF USE TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014760-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | CYP1A2 2665/4885CYP2D6 3362/4885DNMT1 2539/4885 |
| US-20100137566-A1 | Compounds and Methods Used to Treat Infectious Diseases | KPNA1, NFATC1, MAVS | CYP1A2 2824/4885CYP2D6 3706/4885DNMT1 2519/4885 |
| US-20020077271-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | CYP1A2 2665/4885CYP2D6 3362/4885DNMT1 2539/4885 |
| US-20040053815-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | CYP1A2 2665/4885CYP2D6 3362/4885DNMT1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.